Clinical Trial: Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines

U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07013279) titled 'Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines' on June 02.

Brief Summary: To evaluate the efficacy and safety of DWP712 Inj. in Subjects with Moderate to Severe Glabellar Lines

Study Start Date: July 15

Study Type: INTERVENTIONAL

Condition: Glabellar Lines

Intervention: BIOLOGICAL: DWP712 inj.

Clostridium botulinum Toxin

BIOLOGICAL: Botox(R) 100 Units

Clostridium botulinum Toxin

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Daewoong Pharmaceutical Co. LTD.

Published by HT Digital Content Services with permission from Health Daily Digest....